The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,629.00
Bid: 1,629.00
Ask: 1,629.50
Change: -11.00 (-0.67%)
Spread: 0.50 (0.031%)
Open: 1,633.00
High: 1,641.00
Low: 1,611.00
Prev. Close: 1,640.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GlaxoSmithKline Sets New Gender And Diversity Targets For 2025

Wed, 17th Feb 2021 19:14

(Alliance News) - Drug maker GlaxoSmithKline PLC on Wednesday announced new gender and diversity targets for increasing representation at senior levels.

The company has set aspirational targets to increase ethnic diversity among US and UK senior leadership and further extended is gender diversity aspirational target in order to "drive further progress".

The company said it has already beaten a previous target for 37% vice president-level and above roles being filled by women. It will now extend this to at least 45% by 2025.

Moreover, it has introduced targets for racial and ethnic diversity in senior roles in its two largest employee populations, being the US and UK, which reflect those countries' demographics.

In the US, it is aiming for at least 30% ethnically diverse leaders by 2025-end, from the current level of 23%, while in the UK the target is at least 18% ethnically diverse leaders by the end of 2025, from 11% at present.

Glaxo noted that: "While the expectation is progress across all groups during that time, there will be a specific focus in the US to increase the percentage of Black or African American, and Hispanic or Latinx senior leaders and to increase the percentage of Black senior leaders in the UK year-on-year."

The targets, Glaxo said, are part of a broader commitment to diversity and inclusion and aim of increasing these across all different groups of people in the company's workforce.

Chief Executive Emma Walmsley said: "We have already made some good progress on our inclusion and diversity agenda, but there is still much more we can do. These new ambitions are the next step for us as we build a diverse workforce that represents the society we operate in and ultimately helps us provide more effective solutions for patients and consumers."

Shares in Glaxo closed 0.3% higher at 1,276.40 pence in London on Wednesday.

By Anna Farley; annafarley@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
11 Oct 2023 07:47

LONDON BRIEFING: Stocks lower; GSK settles Zantac case in California

(Alliance News) - Stocks in London are set to open lower on Wednesday as investor looked ahead to the release of the US Federal Reserve's September meeting minutes later in the day.

Read more
9 Oct 2023 08:16

TOP NEWS: GSK inks agreement with Zhifei to promote shingles vaccine

(Alliance News) - GSK PLC on Monday said it has reached an exclusive agreement with Chongqing Zhifei Biological Products Ltd to co-promote its shingles vaccine, Shingrix, in China.

Read more
9 Oct 2023 07:42

LONDON BRIEFING: Metro Bank secures deal to shore up finances

(Alliance News) - Stocks in London are set to open higher on Monday as interest rate expectations held steady despite Friday's bumper US nonfarm payrolls report.

Read more
9 Oct 2023 07:20

GSK inks deal to promote shingles vaccine in China

(Sharecast News) - GSK has entered into a new exclusive vaccine partnership in China that will extend the availability of its shingle vaccine Shingrix, which will see the UK-listed group generate £2.5bn over the next three years.

Read more
8 Oct 2023 11:36

Sunday newspaper round-up: Renewi, Metro Bank, New homes

(Sharecast News) - Some of Renewi's major shareholders are divided as to whether the recycling company should engage with Australian suitor Macquarie. One major shareholder has told Renewi's board that it should not until Macquarie raised its £636m bid, but another top ten shareholder told The Sunday Times that it should talk to the Australian outfit anyways. Macquarie has until 26 October to make a firm offer. - The Sunday Times

Read more
6 Oct 2023 08:17

GSK raises £885.6m from Haleon share sale

(Sharecast News) - GSK said on Friday that it has sold 270m shares in Haleon - the consumer health business it spun off last year - raising around £885.6m.

Read more
6 Oct 2023 07:57

UPDATE: GSK banks GBP886 million from Haleon share sale

(Alliance News) - GSK PLC on Friday said it received GBP885.6 million in gross proceeds from its sale of shares in consumer healthcare spin-off Haleon PLC.

Read more
6 Oct 2023 07:46

LONDON BRIEFING: Wetherspoon swings to profit; UK house prices fall

(Alliance News) - Stocks in London are called to open higher on Friday, as investors eye a key nonfarm payroll reading in the US.

Read more
5 Oct 2023 15:47

UK dividends calendar - next 7 days

Friday 6 October 
Admiral Group PLCdividend payment date
Alfa Financial Software Holdings PLCspecial dividend payment date
Anglo-Eastern Plantations PLCdividend payment date
Blackrock World Mining Trust PLCdividend payment date
Cairn Homes PLCdividend payment date
Dalata Hotel Group PLCdividend payment date
Drax Group PLCdividend payment date
Glanbia PLCdividend payment date
GlobalData PLCdividend payment date
Goodwin PLCdividend payment date
Greggs PLCdividend payment date
Intertek Group PLCdividend payment date
Irish Continental Group PLCdividend payment date
JPMorgan American Investment Trust PLCdividend payment date
JPMorgan Global Growth & Income PLCdividend payment date
Land Securities Group PLCdividend payment date
Personal Assets Trust PLCdividend payment date
Quartix Technologies PLCdividend payment date
Serco Group PLCdividend payment date
Walker Crips Group PLCdividend payment date
Warehouse REIT PLCdividend payment date
Zotefoams PLCdividend payment date
Monday 9 October 
Henderson Smaller Cos Investment Trust PLCdividend payment date
LondonMetric Property PLCdividend payment date
Tuesday 10 October 
LSL Property Services PLCdividend payment date
Wednesday 11 October 
Assura PLCdividend payment date
Rathbones Group PLCdividend payment date
Thursday 12 October 
Blackrock Latin American Investment Trust PLCex-dividend payment date
Breedon Group PLCex-dividend payment date
Diageo PLCdividend payment date
GSK PLCdividend payment date
Howden Joinery Group PLCex-dividend payment date
i3 Energy PLCex-dividend payment date
Invesco Bond Income Plus Ltdex-dividend payment date
JPMorgan Asia Growth & Income PLCex-dividend payment date
JPMorgan Mid Cap Investment Trust PLCex-dividend payment date
Kingfisher PLCex-dividend payment date
MP Evans Group PLCex-dividend payment date
Macfarlane Group PLCdividend payment date
North American Income Trust PLCex-dividend payment date
Oxford Instruments PLCdividend payment date
Persimmon PLCex-dividend payment date
Personal Group Holdings PLCex-dividend payment date
Primary Health Properties PLCex-dividend payment date
Ruffer Investment Co Ltdex-dividend payment date
Senior PLCex-dividend payment date
Spirax-Sarco Engineering PLCex-dividend payment date
Strategic Equity Capital PLCex-dividend payment date
Supermarket Income REIT PLCex-dividend payment date
Taylor Wimpey PLCex-dividend payment date
Tesco PLCex-dividend payment date
TT Electronics PLCdividend payment date
WPP PLCex-dividend payment date
XP Power Ltddividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
3 Oct 2023 18:19

IN BRIEF: GSK's Jemperli approved in UK for endometrial cancer

GSK PLC - London-based pharmaceutical company - On Monday, announces that the UK Medicines & Health Products Regulatory Agency has authorised a new indication for Jemperli, also known as dostarlimab. The drug is used as a treatment for some types of endometrial cancer and an be used to treat patients that have a tumour abnormality called mismatch repair deficient/microsatellite instability-high when the cancer is at an advanced stage when first diagnosed or has returned after previous treatment. It is now authorised to be used together with chemotherapy to slow the progression of these cancers. GSK says it is the first medicine licensed as first line treatment for primary advanced or recurrent endometrial cancer.

Read more
3 Oct 2023 11:59

LONDON MARKET MIDDAY: HSBC and StanChart help FTSE 100 outperform

(Alliance News) - London's FTSE 100 grew in confidence as Tuesday morning progressed, going into the afternoon in the green and outperforming European peers.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 08:37

TOP NEWS: GSK's Arexvy vaccine approved for adults over 60 in Japan

(Alliance News) - GSK PLC on Monday said the Japan Ministry of Health, Labour & Welfare has approved Arexvy for adults over 60.

Read more
25 Sep 2023 07:28

GSK's RSV vaccine gets approval in Japan

(Sharecast News) - GSK announced on Monday that its vaccine, Arexvy, has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for preventing respiratory syncytial virus (RSV) disease in adults aged 60 and over.

Read more
19 Sep 2023 09:30

GSK says new HIV PrEP medication authorised by European Commission

(Alliance News) - GSK PLC on Tuesday said the European Commission has authorised ViiV Healthcare's "superior" drug Apretude to reduce the risk of sexually acquired HIV-1 infection.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.